QuidelOrtho Ends Stockholder Agreement Amid Stock Offering

QuidelOrtho Corporation (NASDAQ: QDEL) has announced the termination of its Principal Stockholders Agreement with its Selling Stockholder. This change follows the decision by the Selling Stockholder to sell its shares, which were previously held in ordinary business operations. Consequently, the Selling Stockholder will no longer have the right to nominate members to QuidelOrtho's Board of Directors.

The stock offering is being conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Investors are encouraged to review the prospectus and related documents available on the SEC's EDGAR website for comprehensive details about the offering.

QuidelOrtho emphasizes that this announcement does not constitute an offer to sell or solicitation to buy securities in any jurisdiction where such actions would be unlawful.

QuidelOrtho Corporation is a leader in in vitro diagnostics, providing advanced solutions in immunoassay, molecular testing, clinical chemistry, and transfusion medicine. The company is dedicated to delivering fast, accurate diagnostics to various healthcare settings worldwide.

For further information, the prospectus can be obtained from Goldman Sachs & Co. LLC or accessed online via the SEC's website.